GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Purchase Of Property, Plant, Equipment

SKYE (Skye Bioscience) Purchase Of Property, Plant, Equipment : $-1.56 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Purchase Of Property, Plant, Equipment?

Skye Bioscience's purchase of property, plant, equipment for the three months ended in Sep. 2024 was $-1.52 Mil. It means Skye Bioscience spent $1.52 Mil on purchasing property, plant, equipment. Skye Bioscience's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.56Mil.

Compared with last quarter ($-0.03 Mil in Jun. 2024 ), Skye Bioscience spent more money on purchasing property, plant, equipment in Sep. 2024 ($-1.52 Mil).

Skye Bioscience Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for Skye Bioscience's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Purchase Of Property, Plant, Equipment Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 -0.09 -0.03 -0.01

Skye Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - -0.03 -1.52

Skye Bioscience Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Skye Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Purchase Of Property, Plant, Equipment
Comparable Companies
ELEV UNCY VINC ACER HEPA NLSP HARP NBIO ICU AIM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Website
https://www.skyebioscience.com
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Executives
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Kaitlyn Melanie Arsenault officer: Chief Financial Officer 11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC., SAN DIEGO CA 92130
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107